Drug Information

Drug General Information
Drug ID
D0N3SH
Former ID
DCL001119
Drug Name
Pyroxamide
Synonyms
POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Discontinued in Phase 1 [547711]
Company
National Cancer Institute (NCI)
Structure
Download
2D MOL

3D MOL
Formula
C13H19N3O3
Canonical SMILES
C1=CC(=CN=C1)NC(=O)CCCCCCC(=O)NO
InChI
1S/C13H19N3O3/c17-12(15-11-6-5-9-14-10-11)7-3-1-2-4-8-13(18)16-19/h5-6,9-10,19H,1-4,7-8H2,(H,15,17)(H,16,18)
InChIKey
PTJGLFIIZFVFJV-UHFFFAOYSA-N
PubChem Compound ID
4996
PubChem Substance ID
524991, 4608854, 8153077, 11438689, 12015417, 14848177, 29224069, 50603092, 57322560, 87226485, 99375471, 103418141, 103841418, 104004372, 104253510, 104307980, 117537758, 124757633, 125164437, 126660957, 126731468, 135088920, 136340341, 136367808, 139449345, 143499434, 152039182, 152234894, 152344512, 162011454, 162037804, 162205056, 162403572, 163180667, 163908018, 164042817, 174006330, 177748468, 198971555, 223385536, 223496134, 223669160, 223704764, 226519078, 242059956, 247285530, 249582969, 252158030, 252160464, 252220198
Target and Pathway
Target(s) Histone deacetylase 1 Target Info Inhibitor [536272], [536509]
KEGG Pathway Cell cycle
Notch signaling pathway
Thyroid hormone signaling pathway
Huntington's disease
Amphetamine addiction
Alcoholism
Epstein-Barr virus infection
Pathways in cancer
Transcriptional misregulation in cancer
Viral carcinogenesis
MicroRNAs in cancer
Chronic myeloid leukemia
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Wnt signaling pathway
p53 pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Notch signaling pathway
E2F transcription factor network
Presenilin action in Notch and Wnt signaling
Signaling events mediated by HDAC Class I
Regulation of Telomerase
Glucocorticoid receptor regulatory network
Sumoylation by RanBP2 regulates transcriptional repression
Regulation of Androgen receptor activity
IL3-mediated signaling events
Validated nuclear estrogen receptor alpha network
Retinoic acid receptors-mediated signaling
Hedgehog signaling events mediated by Gli proteins
Regulation of nuclear beta catenin signaling and target gene transcription
Validated targets of C-MYC transcriptional repression
Regulation of retinoblastoma protein
Notch-mediated HES/HEY network
Reactome G0 and Early G1
p75NTR negatively regulates cell cycle via SC1
Formation of the beta-catenin:TCF transactivating complex
NOTCH1 Intracellular Domain Regulates Transcription
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
Constitutive Signaling by NOTCH1 PEST Domain Mutants
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
HDACs deacetylate histones
Deactivation of the beta-catenin transactivating complex
NoRC negatively regulates rRNA expression
RNA Polymerase I Transcription Initiation
Factors involved in megakaryocyte development and platelet production
WikiPathways SIDS Susceptibility Pathways
Notch Signaling Pathway
TGF beta Signaling Pathway
IL-6 signaling pathway
Apoptosis-related network due to altered Notch3 in ovarian cancer
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
Notch Signaling Pathway
Retinoblastoma (RB) in Cancer
Neural Crest Differentiation
TWEAK Signaling Pathway
Integrated Breast Cancer Pathway
Signalling by NGF
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
Mitotic G1-G1/S phases
Factors involved in megakaryocyte development and platelet production
Cell Cycle
Androgen receptor signaling pathway
References
Ref 547711Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018698)
Ref 536272Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
Ref 536509Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.